All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View ALL content recommended for you
Results from a 5-year analysis of the global, multicenter, phase II ELIANA trial (NCT02435849), evaluating the efficacy and safety of tisagenlecleucel (tisa-cel) in pediatric and young adult patients aged 3–25 years with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), were published in the Journal of Clinical Oncology by Grupp et al. Key end points included relapse-free survival (RFS), overall survival (OS), and safety.
Key data: At a median follow-up of 79.4 months, 88.6% of patients receiving tisa-cel (N = 79) had a best overall response (BOR) of complete remission (CR) / CR with incomplete blood count recovery (CRi). Among responders (n = 70), 17 underwent post-infusion stem cell transplantation (SCT), including 14 who remained in CR at transplantation. The estimated 5-year RFS among responders was 47.3% with censoring for all subsequent anticancer therapies, including SCT, and 51.0% when censoring for all further therapies except SCT; estimated 5-year OS rates were 55.0% and 62.4%, with censoring for new anticancer therapies including or excluding SCT, respectively. B-cell aplasia was sustained in 62% of patients who had CR/CRi within 3 months (n = 65). No new or unexpected safety signals were reported.
Key learning: In this 5-year analysis, tisa-cel demonstrated durable responses and long-term survival, with no new safety signals reported in pediatric and young adult patients with R/R B-ALL. These findings support its potential as definitive therapy for this patient population.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.